Events or circumstances that raise substantial doubt about the going-concern assumption
ADRバイオメディカルホールディングス株式会社 Group
The entire group. Related products listed include the Cellution centrifuge, Cellution Cell Therapy Kit, Cellution Cell Therapy Kit SUI and Neocella.
The company requires substantial research and development funding as a research-driven company, and long-term upfront investment continues due to the burden of research and development expenses. Operating losses and negative operating cash flow continue to be generated, and the company had negative net assets at the end of the interim consolidated accounting period. In addition, the method, amount and timing of further financing for the period from the fiscal year ending March 2028 onward or for one year after the financial statements are released have not been determined.
Interim net loss attributable to owners of the parent: ¥224.677 million; cash flow from operating activities: negative ¥421.949 million; net assets: negative ¥202.694 million. Recorded a settlement loss of ¥15.676 million as an extraordinary loss.
1 April 2026–30 September 2026 (interim consolidated accounting period)
No change to the full-year consolidated earnings forecast announced on 15 May 2026. For the fiscal year ending March 2027, revenue, operating income, ordinary income and net income attributable to owners of the parent are expected to improve substantially from the fiscal year ended March 2026.
Related procedures
Ministry of Health, Labour and Welfare (only descriptions concerning marketing authorisation and health insurance coverage)
The company will promote research and development activities, the transition to domestically manufactured products, business expansion in new fields, cost reductions, improvement of its financial position and financing. It received a ¥400 million debt waiver from 株式会社HGキャピタル and continued access to a committed credit line with a maximum facility of ¥500 million, and borrowed ¥370 million during the interim consolidated accounting period. However, the method, amount and timing of the additional financing required from the fiscal year ending March 2028 onward or for one year after the financial statements are released remain undetermined.
| Item | Details |
|---|---|
| Event name | Events or circumstances that raise substantial doubt about the going-concern assumption |
| Date of occurrence | 30 September 2026 (when the company became insolvent on a net-assets basis at the end of the interim consolidated accounting period) |
| Subject Entity | ADRバイオメディカルホールディングス株式会社 Group |
| Target Locations / Products | The entire group. Related products listed include the Cellution centrifuge, Cellution Cell Therapy Kit, Cellution Cell Therapy Kit SUI and Neocella. |
| Cause | The company requires substantial research and development funding as a research-driven company, and long-term upfront investment continues due to the burden of research and development expenses. Operating losses and negative operating cash flow continue to be generated, and the company had negative net assets at the end of the interim consolidated accounting period. In addition, the method, amount and timing of further financing for the period from the fiscal year ending March 2028 onward or for one year after the financial statements are released have not been determined. |
| Amount of Impact on Business Performance | Interim net loss attributable to owners of the parent: ¥224.677 million; cash flow from operating activities: negative ¥421.949 million; net assets: negative ¥202.694 million. Recorded a settlement loss of ¥15.676 million as an extraordinary loss. |
| Accounting period in which recognized | 1 April 2026–30 September 2026 (interim consolidated accounting period) |
| Impact on Earnings Forecast | No change to the full-year consolidated earnings forecast announced on 15 May 2026. For the fiscal year ending March 2027, revenue, operating income, ordinary income and net income attributable to owners of the parent are expected to improve substantially from the fiscal year ended March 2026. |
| Court or authority | Ministry of Health, Labour and Welfare (only descriptions concerning marketing authorisation and health insurance coverage) |
| Outlook | The company will promote research and development activities, the transition to domestically manufactured products, business expansion in new fields, cost reductions, improvement of its financial position and financing. It received a ¥400 million debt waiver from 株式会社HGキャピタル and continued access to a committed credit line with a maximum facility of ¥500 million, and borrowed ¥370 million during the interim consolidated accounting period. However, the method, amount and timing of the additional financing required from the fiscal year ending March 2028 onward or for one year after the financial statements are released remain undetermined. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the continuation of long-term upfront investment and substantial research and development expenses as a research-driven company, recurring operating losses and negative operating cash flow, and negative net assets at the end of the interim consolidated accounting period. It also stated that the method, amount and timing of the additional financing required to continue operations from the fiscal year ending March 2028 onward or for one year after the financial statements are released have not been determined.